Kura Oncology (KURA) Change in Accured Expenses (2010 - 2026)

Kura Oncology (KURA) has 14 years of Change in Accured Expenses data on file, last reported at -$16.2 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$16.2 million, down 88.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (down 55.45% YoY), and the FY2025 annual result was $12.7 million, down 24.8% from the prior year.
• Change in Accured Expenses slipped to -$16.2 million in Q1 2026 per KURA's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $14.3 million in Q4 2024 and troughed at -$16.2 million in Q1 2026.
• A 5-year average of $1.4 million and a median of -$50000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses plunged 5132.26% in 2022, then jumped 21524.0% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2022, then jumped by 649.36% to $8.6 million in 2023, then soared by 67.2% to $14.3 million in 2024, then sank by 115.07% to -$2.2 million in 2025, then sank by 650.74% to -$16.2 million in 2026.
• Business Quant data shows KURA's Change in Accured Expenses at -$16.2 million in Q1 2026, -$2.2 million in Q4 2025, and $12.7 million in Q3 2025.